Intensity-Modulated Radiotherapy of the Prostate After Cryotherapy: Initial Experience

Urology

Volumn 72, Issue 6, 2008, Pages 1310-1314

  Hepel, Jaroslaw T ^a,b   MacAusland, Stephanie G ^a,b   Long, John P ^c   Wazer, David E ^a,b   DiPetrillo, Thomas ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c New England Urology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; SALVAGE THERAPY; TREATMENT FAILURE; UROGENITAL TRACT DISEASE;

ADENOCARCINOMA; AGED; BIOPSY; CRYOTHERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; RISK; SALVAGE THERAPY; TEMPERATURE; TREATMENT OUTCOME;

EID: 56449089286     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.01.079     Document Type: Article

References (21)

1. Shinohara K. Prostate cancer: cryotherapy. Urol Clin N Am 30 (2003) 725-736
2. Lee F., Bahn D.K., McHugh T.A., et al. Cryosurgery of prostate cancer: use of adjuvant hormonal therapy and temperature monitoring-a one year follow-up. Anticancer Res 17 (1997) 1511-1555
3. Badalament R.A., Bahn D.K., Kim H., et al. Patient-reported complications after cryoablation therapy for prostate cancer. Arch Ital Urol Androl 7 (2000) 305-312
4. Long J.P., Bahn D., Lee F., et al. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Adult Urol 57 3 (2001) 518-523
5. Bahn D.K., Lee F., Badalament R., et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 60 (2002) 3-11
6. Derakhshani P., Neubauer S., Braun M., et al. Cryoablation of localized prostate cancer. Experience in 48 cases, PSA and biopsy results. Eur Urol 34 (1998) 181-187
7. Cox R.L., and Crawford E.D. Complications of cryosurgical ablation of the prostate to treat localized adenocarcinoma of the prostate. Urology 45 6 (1995) 932-935
8. Burton S., Brown D.M., Colonias A., et al. Salvage radiotherapy for prostate cancer recurrence after cryosurgical ablation. Adult Urol 56 5 (2000) 833-838
9. McDonough M.J., Feldmeier J.J., Parsai I., et al. Salvage external beam radiotherapy for clinical failure after cryosurgery for prostate cancer. Int J Rad Onc Biol Phys 51 3 (2001) 624-627
10. Pollack A., Zagars G.k., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70Gy with 78Gy for prostate cancer. J Clin Oncol 18 (2000) 3904-3911
11. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional dose vs. high dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 294 (2005) 1233-1239
12. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (2005) 1192-1199
13. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 166 (2001) 2185-2188
14. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 65 4 (2006) 964-974
15. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 5 (2002) 1111-1116
16. Leibel S.A., Fuks Z., Zelefsky M.J., et al. Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer. Semin Oncol 30 5 (2003) 596-615
17. Beckendorf V., Guerif S., Le Prise E., et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 60 4 (2004) 1056-1065
18. Smit W.G., Helle P.A., Van Putten W.L., et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 18 (1990) 23-29
19. Huang E.H., Pollack A., Levy L., et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 54 5 (2002) 1314-1321
20. Vargas C., Yan D., Kestin L.L., et al. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity. Int J Radiat Oncol Biol Phys 63 1 (2005) 141-149
21. Adusumilli S., and Pretorius E.S. Magnetic resonance imaging of prostate cancer. Semin Urol Oncol 20 3 (2002) 192-210